Introduction
Materials and methods
About the protocol
Groups
Characteristics of patients
Characteristics | Group 1 (n = 12) | Group 2 (n = 12) | Group 3 (n = 23) |
---|---|---|---|
Age (years) | 61 ± 18 | 58 ± 16 | 60 ± 15 |
Sex (cases) | |||
Female | 7 | 6 | 9 |
Male | 5 | 6 | 14 |
Lesion size (mm) | |||
Length | 25.25 ± 3.05 | 13.00 ± 6.00 | 20.50 ± 5.00 |
Width | 14.42 ± 4.81 | 9.42 ± 3.61 | 15.00 ± 4.30 |
Height | 16.42 ± 2.31 | 7.33 ± 2.78 | 13.00 ± 6.50 |
Location and cases of each lobe | |||
Right (left) upper lobe | 2 | 2 | 6 |
Right middle (left lingular) lobe | 2 | 2 | 5 |
Right (left) lower lobe | 2 | 2 | 12 |
CT findings (Types and Cases) | |||
GGO | 0 | 5 | 5 |
mGGO | 4 | 2 | 6 |
SPNs | 8 | 5 | 12 |
Bronchoscopy procedures
Bronchoscope was advanced to segment where the lesion located
Visible lesion under fluoroscopy
Lesions were located accurately by our techniques and performed bronchoscopy procedures
ROSE
Brief case report involving our techniques
EBUS procedures
Statistical analysis
Results
Results of patients performed bronchoscopy under fluoroscopy
N
| Location | CT finding | Size (mm) | Distance to pleura (mm) | Visible or not | Histology results from bronchoscopy | Final diagnosis | Fluoroscopy time (min) |
---|---|---|---|---|---|---|---|---|
1 | RUL | mGGO | 30*15*15 | 15 | Visible | Adenocarcinoma | Adenocarcinoma | 7.5 |
2 | RLL | SPN | 12*10*11 | 10 | Invisible | Negative | Adenocarcinoma | 9.0 |
3 | LM(L)L | mGGO | 18*15*10 | 8 | Invisible | Inflammation | Inflammation | 9.5 |
4 | RLL | SPN | 25*15*14 | 18 | Visible | Inflammation? | Adenocarcinoma | 7.0 |
5 | RML | GGO | 3*4*3 | 0 | Invisible | Negative | Inflammation | 10.0 |
6 | LUL | SPN | 26*18*16 | 10 | Visible | Caseous necrosis | Caseous necrosis | 5.5 |
7 | LUL | SPN | 25*11*15 | 5 | Visible | Carcinoma cells | Adenocarcinoma | 6.5 |
8 | LLL | SPN | 9*8*5 | 10 | Invisible | Negative | AAH | 10.0 |
9 | LUL | GGO | 4*3*3 | 15 | Invisible | Negative | Inflammation | 10.0 |
10 | RML | SPN | 25*16*17 | 22 | Visible | Atypical cells | AAH | 4.5 |
11 | LULΔ | SPN | 10*10*9 | 15 | Invisible | Squamous cell carcinoma | Squamous cell carcinoma | 8.0 |
12 | LLL | SPN | 20*20*15 | 0 | Visible | Carcinoma cells | Adenocarcinoma | 7.5 |
13 | RML | mGGO | 22*8*16 | 10 | Visible | Negative | Adenocarcinoma | 6.5 |
14 | RUL | SPN | 20*8*6 | 20 | Invisible | Squamous cell carcinoma | Squamous cell carcinoma | 5.0 |
15 | RUL | mGGO | 25*12*16 | 15 | Visible | Negative | Caseous necrosis | 5.5 |
16 | RML | GGO | 11*13*7 | 20 | Invisible | Carcinomacells | Small cell carcinoma | 6.5 |
17 | LM(L)L | mGGO | 30*11*20 | 0 | Visible | Poorly differentiated carcinoma | Poorly differentiated carcinoma | 7.5 |
18 | RUL | SPN | 18*8*10 | 30 | Invisible | Carcinoma cells | Squamous cell carcinoma | 4.5 |
19 | RLL | SPN | 25*15*22 | 28 | Visible | Small cell carcinoma | Small cell carcinoma | 4.0 |
20 | RLL | GGO | 19*14*6 | 30 | Invisible | Negative | Squamous cell carcinoma | 6.0 |
21 | LLL | SPN | 22*10*16 | 30 | Visible | Negative | Inflammation | 3.5 |
22 | LM(L)L | SPN | 25*12*15 | 32 | Visible | Adenocarcinoma | Adenocarcinoma | 4.5 |
23 | LLL* | mGGO | 20*10*8 | 35 | Invisible | Carcinoma cells | Adenocarcinoma | 7.0 |
24 | LM(L)L | GGO | 12*10*10 | 25 | Invisible | Carcinoma cells | Large cell carcinoma | 6.5 |
Visible lesion under fluoroscopy
Results of patients performed bronchoscopy with R-EBUS-GS
ROSE results
Accuracy rates of diagnostic cases guided by fluoroscopy guided FB or R-EBUS
Methods Cases Items | Lesion location | CT scan findings | Lesion under fluoroscopy or EBUS | ||||||
---|---|---|---|---|---|---|---|---|---|
UL | ML | LL | SPN | mGGO | GGO | Visible | Invisible | ||
Flu-FB | Cases enrolled | 8 | 8 | 8 | 13 | 6 | 5 | 12 | 12 |
Accurate diagnosis | 6 | 6 | 3 | 9 | 4 | 2 | 8 | 7 | |
EBUS | Cases enrolled | 6 | 5 | 12 | 12 | 6 | 5 | 19 | 4 |
Accurate diagnosis | 3 | 3 | 9 | 10 | 4 | 1 | 15 | 0 |